Papers: 17 Dec 2012 - 24 Dec 2012
B-cell enrichment and epstein-barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis.
Confounding Parameters in Pre-clinical Assessment of Blood-brain Barrier Permeation: An Overview With Emphasis on Species Differences and Effect of Disease States.
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica.
Serious Complication of Percutaneous Angioplasty with Stent Implantation in so Called "Chronic Cerebrospinal Venous Insufficiency" in Multiple Sclerosis Patient.
The Prevalence of the Classical and non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients.
Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Olfactory Dysfunction in Multiple Sclerosis: Evidence of a Decrease in Different Aspects of Olfactory Function.
Pediatric Multiple Sclerosis with Primary Progressive Course-Report of a Retrospective Cohort Study in Iran.
High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients.
Heterogeneous nuclear ribonucleoprotein A1 in health and neurodegenerative disease: From structural insights to post-transcriptional regulatory roles.
Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic.
The Falls Efficacy Scale International: A Cross-Sectional Validation in People with Multiple Sclerosis.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Relative incidence of inherited white matter disorders in childhood to acquired pediatric demyelinating disorders.
A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis.
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun.
[Pharmaceutical prescription for multiple sclerosis : Evaluation of pharmaceutical consumption at private health insurance.]
Decrease of mutual information in brain electrical activity of patients with relapsing-remitting multiple sclerosis.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Spinal cord lesions in patients with clinically isolated syndrome: A powerful tool in diagnosis and prognosis.
Preventive treatment with methylprednisolone paradoxically exacerbates experimental autoimmune encephalomyelitis.
Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D.